Soligenix Gets Fast Track Designation for Gastrointestinal Acute Radiation Syndrome Treatment

Soligenix, Inc. (OTCBB: SNGX) said Tuesday morning that the Food and Drug Administration has granted a “Fast Track” designation for OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP), the company’s treatment in development for the reduction of mortality associated with Gastrointestinal Acute Radiation Syndrome, or GI ARS.

The FDA grants Fast Track designations to expedite development of drugs or therapies that may address a significant area of unmet medical need.

There are not FDA approved therapies for the treatment of GI ARS, a condition occurring after toxic radiation exposure that affects several organ systems, explained Dr. Christopher Schaber, president and chief executive of Soligenix in a corporate statement.

“We look forward to working closely with the FDA, as well as with the National Institute of Allergy and Infectious Disease (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) to potentially expedite the OrbeShield development program,” said Schaber.

High levels of radiation exposure, such as that in a nuclear disaster, can cause severe damage to the gastrointestinal system and result in death in 5 to 15 days, according to the Princeton, New Jersey-based company.

Earlier this month, Soligenix received Orphan Drug designation from the FDA for OrbeShield for a treatment after exposure to a radiological disaster. Orphan drug designations are given to support and encourage the development of drugs or therapies focused on rare diseases or disorders.

Shares of SNGX have been on a strong climb over the past six months, rising from 23 cents in the last days of June to Monday’s closing price of $1.46 for gains in excess of 530 percent. Shares are currently at the highest level since early in September 2011 when share value plummeted 85 percent on news that an independent Data Safety Monitoring Board recommended the cessation of a phase III clinical trial for acute gastrointestinal graft-versus-host disease.

Soligenix Inc. (SNGX) Stock Quote and News:

Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

	Stocks Mixed on Monday(0) The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

	Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0) The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

	EnteroMedics Stock Chart Analysis Video(0) The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

	NXT-ID Authentication Using Face and Voice Recognition(0) There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

	Dow Not Tired of Making New Record Highs(0) The Dow Jones Industrials will have to wait till at least next week to mount the lofty heights of 16,000 points, but both the Dow and the S&P did end the day at record highs. The Dow Jones Industrials was up 85.48 points from yesterday”s all-time high, to close at 15,961.70 The S&P 500 index

Stay Informed

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.